ClinicalTrials.gg

Program

fexuprazan

Also written as “DWP14012”, “DWP14012 20mg” and “DWP14012 40mg”.

Its studies are mostly in Esophagitis · Gastroesophageal Reflux · Stomach Ulcer · Peptic Ulcer · Non-Erosive Reflux Disease, led by 2 companies.

Furthest: phase 4, since Apr 8, 202629 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceutical285 open or runningphase 4since Apr 8, 2026Mar 16, 2016Dec 2027phase 4 · NCT07533266
GlaxoSmithKline10 open or runningphase 1since Dec 15, 2011Dec 15, 2011none ahead

Also a collaborator on its studies: shanghai-haini-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Dec 15, 2011.

  1. Oct 28, 2020No phase study in Erosive EsophagitisDaewoong Pharmaceutical · NCT04613895 · 186 enrolled · Korea, Republic of
  2. Mar 3, 2021Phase 3 study in Peptic UlcerDaewoong Pharmaceutical · NCT04784910 · 423 enrolled · Korea, Republic of
  3. Mar 25, 2021Phase 1 study in HealthyDaewoong Pharmaceutical · NCT04827472 · 36 enrolled · Korea, Republic of
  4. Dec 15, 2021Phase 1 study in Healthy VolunteersDaewoong Pharmaceutical · NCT06508645 · 33 enrolled · South Korea
  5. Mar 16, 2022Phase 1 study in Drug Drug InteractionDaewoong Pharmaceutical · NCT05304845 · 24 enrolled · Korea, Republic of
  6. Sep 4, 2022Phase 1 study in Drug Drug InteractionDaewoong Pharmaceutical · NCT05574374 · 36 enrolled · Korea, Republic of
  7. Nov 14, 2022Phase 1 study in Drug Drug InteractionDaewoong Pharmaceutical · NCT05812404 · 36 enrolled · Korea, Republic of
  8. Apr 2, 2023Phase 3 study in Esophagitis, PepticDaewoong Pharmaceutical · NCT05813561 · 332 enrolled · China
  9. Apr 7, 2023Phase 1 study in Phase 1 Study, Healthy VolunteersDaewoong Pharmaceutical · NCT05868967 · 8 enrolled · China
  10. Oct 16, 2023Phase 3 study in Non-Erosive Reflux DiseaseDaewoong Pharmaceutical · NCT06121830 · 324 planned · Korea, Republic of
  11. May 13, 2024Phase 1 study in Erosive Gastroesophageal Reflux DiseaseDaewoong Pharmaceutical · NCT06437951 · 40 enrolled
  12. Dec 20, 2024Phase 3 study in Helicobacter Pylori InfectionDaewoong Pharmaceutical · NCT06751121 · 461 enrolled · South Korea
  13. Apr 8, 2026Phase 4 study in NSAID (Non-Steroidal Anti-Inflammatory Drug)Daewoong Pharmaceutical · NCT07533266 · 360 planned · South Korea
  14. Jul 1, 20262 phase 3 studiesDaewoong Pharmaceutical · NCT07730138, NCT07746518

Ahead

  1. Dec 2027Primary completion: phase 4 study in NSAID (Non-Steroidal Anti-Inflammatory Drug)Daewoong Pharmaceutical · NCT07533266
  2. Apr 15, 2028Primary completion: phase 3 study in Stomach UlcerDaewoong Pharmaceutical · NCT07730138
  3. Aug 2029Primary completion: phase 3 study in Healed Erosive EsophagitisDaewoong Pharmaceutical · NCT07746518

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07746518Healed Erosive Esophagitis3Not yet recruitingDaewoong PharmaceuticalAug 2029420
NCT07730138Stomach Ulcer · Indonesia, South Korea3Not yet recruitingDaewoong PharmaceuticalApr 15, 2028384
NCT07533266NSAID (Non-Steroidal Anti-Inflammatory Drug) · South Korea4Not yet recruitingDaewoong PharmaceuticalDec 2027360
NCT06751121Helicobacter Pylori Infection · South Korea3CompletedDaewoong PharmaceuticalApr 24, 2025461
NCT06437951Erosive Gastroesophageal Reflux Disease1UNKNOWNDaewoong PharmaceuticalJan 202540
NCT06121830Non-Erosive Reflux Disease · Korea, Republic of3RecruitingDaewoong PharmaceuticalJan 2025324
NCT05868967Phase 1 Study, Healthy Volunteers · China1Active, not recruitingDaewoong PharmaceuticalMay 31, 20238
NCT05813561Esophagitis, Peptic · China3CompletedDaewoong PharmaceuticalJul 23, 2022332
NCT05812404Drug Drug Interaction · Korea, Republic of1UNKNOWNDaewoong PharmaceuticalMar 28, 202336
NCT05574374Drug Drug Interaction · Korea, Republic of1CompletedDaewoong PharmaceuticalMar 6, 202336
NCT05304845Drug Drug Interaction · Korea, Republic of1CompletedDaewoong PharmaceuticalMay 22, 202224
NCT06508645Healthy Volunteers · South Korea1CompletedDaewoong PharmaceuticalMar 29, 202233
NCT04827472Healthy · Korea, Republic of1UNKNOWNDaewoong PharmaceuticalJun 30, 202136
NCT04784910Peptic Ulcer · Korea, Republic of3CompletedDaewoong PharmaceuticalNov 27, 2023423
NCT04613895Erosive Esophagitis · Korea, Republic of–UNKNOWNDaewoong PharmaceuticalMay 30, 2021186
NCT04490434Healthy Male Volunteers · Korea, Republic of1UNKNOWNDaewoong PharmaceuticalAug 31, 2020110
NCT04341454Acute Gastritis · Korea, Republic of3CompletedDaewoong PharmaceuticalAug 4, 2021327
NCT04341428Healed Erosive Esophagitis · Korea, Republic of3UNKNOWNDaewoong PharmaceuticalAug 30, 2021406
NCT04328766Drug-drug Interaction · Australia1CompletedDaewoong PharmaceuticalNov 21, 202036
NCT04185805Healthy · Korea, Republic of1UNKNOWNDaewoong PharmaceuticalFeb 28, 202024
NCT04167267Healthy · Korea, Republic of1UNKNOWNDaewoong PharmaceuticalDec 201924
NCT04003441Healthy · Korea, Republic of1UNKNOWNDaewoong PharmaceuticalAug 201924
NCT03811080Non-Erosive Gastroesophageal Reflux Disease · Korea, Republic of3UNKNOWNDaewoong PharmaceuticalFeb 2020327
NCT03736369Erosive Esophagitis · Korea, Republic of3CompletedDaewoong PharmaceuticalAug 7, 2019263
NCT03574415Healthy Volunteers · Korea, Republic of1CompletedDaewoong PharmaceuticalJan 18, 201980
NCT03487562Healthy · Korea, Republic of1CompletedDaewoong PharmaceuticalJan 11, 201948
NCT03184324Erosive Gastroesophageal Reflux Disease · Korea, Republic of2CompletedDaewoong PharmaceuticalApr 18, 2018211
NCT02757144Healthy · Korea, Republic of1CompletedDaewoong PharmaceuticalFeb 2017120
NCT01495026Prostatic Hyperplasia · Australia1CompletedGlaxoSmithKlineApr 3, 201263

How it is read

Names in the registry

  • “DWP14012”, 10 entries
  • “DWP14012 20mg”, 3 entries
  • “DWP14012 40mg”, 3 entries
  • “DWP14012 tablet A”, 3 entries
  • “DWP14012 tablet B”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.